Boehringer Ingelheim has announced the acquisition of all the shares of NBE-Therapeutics, uA private Swiss biotechnology company focused on antibody-drug conjugates and in advance in Targeted Cancer Therapies Derived from Its Immune-Boosting Platform iADC ™. NBE-Therapeutics’ lead compound, NBE-002, is currently in phase I clinical trials for triple negative breast cancer and other solid tumors. In this way, Boehringer Ingelheim accesses an innovative and unique platform that will be used to create a portfolio of ADC products and to develop possible combinations with other assets from its portfolio of immuno-oncology products.
Michel Pairet, member of the Board of Directors of Boehringer Ingelheim and head of the Innovation Unit, explained that “NBE-Therapeutics’ iADC platform adds exceptional capabilities of action targeting tumors from our product portfolio in oncology. Together with our assets, which act on immune cells, could allow new, more powerful combinations to advance towards effective and long-lasting treatments for patients. This acquisition is a new example of the Boehringer Ingelheim’s long-term strategy to improve our position in the search for innovative treatments against cancer ”.
For its part, Bertrand Damour, Executive Director of NBE-Therapeutics, has stated thate “I am extremely proud of the NBE-Therapeutics team and delighted that Boehringer Ingelheim is recognizing our world-class expertise in the field of ADC. This transaction is a validation of our platform and its potential for el development of next-generation cancer therapies. We wait keep moving forward with NBE-002, our leading compound and anti-ROR1 ADC best in class, and continue in the fight against cancer with Boehringer Ingelheim and its strong clinical development capabilities. “
The total value of the transaction is 1,180 million euros and also includes contingent clinical and regulatory milestones. The acquisition of NBE-Therapeutics will significantly reinforce Boehringer Ingelheim’s strategic focus on cancer cell treatments and complement its existing capabilities in antigen discovery, as well as T-cell activating and antibody technologies. By combining its world-class in-house research and development with that of highly innovative biotech companies, the company is driving the development of innovative treatments and accelerating the advancement to the next generation of cancer treatments.
– .
